117 related articles for article (PubMed ID: 38442919)
1. A propensity score-integrated approach for leveraging external data in a randomized controlled trial with time-to-event endpoints.
Chen WC; Lu N; Wang C; Li H; Song C; Tiwari R; Xu Y; Yue LQ
Pharm Stat; 2024 Mar; ():. PubMed ID: 38442919
[TBL] [Abstract][Full Text] [Related]
2. Propensity score-integrated approach to survival analysis: leveraging external evidence in single-arm studies.
Chen WC; Lu N; Wang C; Li H; Song C; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2022 May; 32(3):400-413. PubMed ID: 35675348
[TBL] [Abstract][Full Text] [Related]
3. Propensity score-integrated power prior approach for augmenting the control arm of a randomized controlled trial by incorporating multiple external data sources.
Lu N; Wang C; Chen WC; Li H; Song C; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2022 Jan; 32(1):158-169. PubMed ID: 34756158
[TBL] [Abstract][Full Text] [Related]
4. Augmenting Both Arms of a Randomized Controlled Trial Using External Data: An Application of the Propensity Score-Integrated Approaches.
Li H; Chen WC; Wang C; Lu N; Song C; Tiwari R; Xu Y; Yue LQ
Stat Biosci; 2022; 14(1):79-89. PubMed ID: 34178164
[TBL] [Abstract][Full Text] [Related]
5. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
7. Visualizing hypothesis tests in survival analysis under anticipated delayed effects.
Jiménez JL; Barrott I; Gasperoni F; Magirr D
Pharm Stat; 2024 May; ():. PubMed ID: 38708672
[TBL] [Abstract][Full Text] [Related]
8. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
[TBL] [Abstract][Full Text] [Related]
9. Conditional borrowing external data to establish a hybrid control arm in randomized clinical trials.
Li H; Tiwari R; Li QH
J Biopharm Stat; 2022 Nov; 32(6):954-968. PubMed ID: 35067183
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data.
Chen WC; Wang C; Li H; Lu N; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2020 May; 30(3):508-520. PubMed ID: 32370640
[TBL] [Abstract][Full Text] [Related]
12. Rectus femoris transfer in children with cerebral palsy: comparing a propensity score-matched observational study to a randomized controlled trial.
Schwartz MH; Ries AJ
Dev Med Child Neurol; 2021 Feb; 63(2):196-203. PubMed ID: 33084049
[TBL] [Abstract][Full Text] [Related]
13. Statistical considerations of designs for single-arm proof-of-concept oncology trial with time-to-event endpoint.
Zhou H; Sun L; Wang M
Contemp Clin Trials; 2023 Jun; 129():107200. PubMed ID: 37068588
[TBL] [Abstract][Full Text] [Related]
14. External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning.
Loiseau N; Trichelair P; He M; Andreux M; Zaslavskiy M; Wainrib G; Blum MGB
BMC Med Res Methodol; 2022 Dec; 22(1):335. PubMed ID: 36577946
[TBL] [Abstract][Full Text] [Related]
15. Statistical Considerations for Sequential Analysis of the Restricted Mean Survival Time for Randomized Clinical Trials.
Lu Y; Tian L
Stat Biopharm Res; 2021; 13(2):210-218. PubMed ID: 33927801
[TBL] [Abstract][Full Text] [Related]
16. Sample size calculation for multi-arm parallel design with restricted mean survival time.
Chen Y; Lam KF; Xu J
Stat Methods Med Res; 2024 Jan; 33(1):130-147. PubMed ID: 38093411
[TBL] [Abstract][Full Text] [Related]
17. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
18. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
[TBL] [Abstract][Full Text] [Related]
19. Two-stage screened selection designs for randomized phase II trials with time-to-event endpoints.
Wu J; Pan H; Hsu CW
Biom J; 2022 Oct; 64(7):1207-1218. PubMed ID: 35661226
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
